Voluntary Faculty
Voluntary faculty are typically clinicians or others who are employed outside of the School but make significant contributions to department programs at the medical center or at affiliate institutions.
Voluntary rank detailsBruce Strober, MD, PhD, FAAD
Clinical ProfessorAbout
Research
Publications
2025
Establishing Consensus on Defining Failure of Topical Therapy in Psoriasis: Recommendations from the International Psoriasis Council
Strober B, Blauvelt A, van de Kerkhof P, Asawanonda P, Chandra R, Gonzalez-Cantero A, Gonzalez C, Matlock B, Maul J, Rob F, Torres T, Skov L. Establishing Consensus on Defining Failure of Topical Therapy in Psoriasis: Recommendations from the International Psoriasis Council. Journal Of The American Academy Of Dermatology 2025 PMID: 40945737, DOI: 10.1016/j.jaad.2025.08.116.Peer-Reviewed Original ResearchSystemic Corticosteroid Use in Atopic Dermatitis: A Position Paper to Inform Safer Clinical Practice and Policy
Burshtein J, Bunick C, Vleugels R, Armstrong A, Golant A, Schlesinger T, Strober B, Song E, Gold L, Lebwohl M. Systemic Corticosteroid Use in Atopic Dermatitis: A Position Paper to Inform Safer Clinical Practice and Policy. Journal Of Investigative Dermatology 2025 PMID: 40914897, DOI: 10.1016/j.jid.2025.08.002.Peer-Reviewed Original Research62300 Long-Term Real-World Achievement of Skin Clearance Treatment Targets and Maintenance of Response in Patients with Moderate to Severe Psoriasis Treated with Risankizumab: 3 Year Results from the CorEvitas Psoriasis Registry
Armstrong A, Ferris L, Duffin K, Sima A, Eckmann T, Beeghly A, Garg V, Bialik B, Patel M, Strober B. 62300 Long-Term Real-World Achievement of Skin Clearance Treatment Targets and Maintenance of Response in Patients with Moderate to Severe Psoriasis Treated with Risankizumab: 3 Year Results from the CorEvitas Psoriasis Registry. Journal Of The American Academy Of Dermatology 2025, 93: ab244. DOI: 10.1016/j.jaad.2025.05.970.Peer-Reviewed Original Research62697 Real-world effectiveness of deucravacitinib in patients with plaque psoriasis: a 6-month analysis of skin clearance from the RePhlect Registry
Lebwohl M, Armstrong A, Varga S, Zhong Y, Merola J, Sima A, Gooderham M, Papp K, Gottlieb A, Napoli A, Strober B. 62697 Real-world effectiveness of deucravacitinib in patients with plaque psoriasis: a 6-month analysis of skin clearance from the RePhlect Registry. Journal Of The American Academy Of Dermatology 2025, 93: ab283. DOI: 10.1016/j.jaad.2025.05.1122.Peer-Reviewed Original Research62396 Real-world effectiveness of deucravacitinib in patients with plaque psoriasis: a 6-month analysis of skin pain, itch, and fatigue from the RePhlect Registry
Strober B, Armstrong A, Papp K, Sima A, Gooderham M, Varga S, Zhuo J, Merola J, Gottlieb A, Napoli A, Lebwohl M. 62396 Real-world effectiveness of deucravacitinib in patients with plaque psoriasis: a 6-month analysis of skin pain, itch, and fatigue from the RePhlect Registry. Journal Of The American Academy Of Dermatology 2025, 93: ab77. DOI: 10.1016/j.jaad.2025.05.313.Peer-Reviewed Original Research63736 SPECTREM: Guselkumab Demonstrates Consistent Significant Clearance Across the Full Range of Low Body Surface Area, Moderate Psoriasis With Special Sites Involvement
Gold L, Strober B, Armstrong A, Alkousakis T, Papp K, Langley R, Choi O, Chan D, Jeyarajah J, Groysman V, Lebwohl M. 63736 SPECTREM: Guselkumab Demonstrates Consistent Significant Clearance Across the Full Range of Low Body Surface Area, Moderate Psoriasis With Special Sites Involvement. Journal Of The American Academy Of Dermatology 2025, 93: ab301. DOI: 10.1016/j.jaad.2025.05.1192.Peer-Reviewed Original Research61353 Real-World Skin Clearance and Quality of Life With Risankizumab in Patients Eligible for Systemic Therapy per International Psoriasis Council Criteria
Strober B, Patel M, Kaldas M, St. John G, Garg V, Sima A, Eckmann T, Beeghly A, Armstrong A. 61353 Real-World Skin Clearance and Quality of Life With Risankizumab in Patients Eligible for Systemic Therapy per International Psoriasis Council Criteria. Journal Of The American Academy Of Dermatology 2025, 93: ab286. DOI: 10.1016/j.jaad.2025.05.1133.Peer-Reviewed Original Research60746 Efficacy of Apremilast for the Treatment of Japanese Patients With Palmoplantar Pustulosis: 52-Week Exploratory Endpoints From a Phase 3, Randomized, Placebo-controlled Study
Okubo Y, Terui T, Kobayashi S, Morita A, Imafuku S, Tada Y, Strober B, Gooderham M, Zhang W, Shimauchi J, Murakami M. 60746 Efficacy of Apremilast for the Treatment of Japanese Patients With Palmoplantar Pustulosis: 52-Week Exploratory Endpoints From a Phase 3, Randomized, Placebo-controlled Study. Journal Of The American Academy Of Dermatology 2025, 93: ab190. DOI: 10.1016/j.jaad.2025.05.756.Peer-Reviewed Original Research62388 The evaluation of adequate clinical response to systemic therapy as measured by the Merit-based Incentive Payment System (MIPS) #410 psoriasis quality measure in patients treated with deucravacitinib: a RePhlect 6-month follow-up study
Armstrong A, Lebwohl M, Varga S, Zhuo J, Gooderham M, McLean R, Papp K, Merola J, Gottlieb A, Napoli A, Strober B. 62388 The evaluation of adequate clinical response to systemic therapy as measured by the Merit-based Incentive Payment System (MIPS) #410 psoriasis quality measure in patients treated with deucravacitinib: a RePhlect 6-month follow-up study. Journal Of The American Academy Of Dermatology 2025, 93: ab316. DOI: 10.1016/j.jaad.2025.05.1247.Peer-Reviewed Original Research62276 Bimekizumab achievement of ‘super response’ using a previously published definition in moderate to severe plaque psoriasis: Results from four phase 3/3b trials
Lebwohl M, Langley R, Strober B, Thaçi D, Armstrong A, Gordon K, Puig L, Davies O, Peterson L, Davis L, Warren R. 62276 Bimekizumab achievement of ‘super response’ using a previously published definition in moderate to severe plaque psoriasis: Results from four phase 3/3b trials. Journal Of The American Academy Of Dermatology 2025, 93: ab23. DOI: 10.1016/j.jaad.2025.05.096.Peer-Reviewed Original Research